FOGHORN THERAPEUTICS INC (FHTX)
US3441741077 - Common Stock
FOGHORN THERAPEUTICS INC
NASDAQ:FHTX (10/18/2024, 8:00:00 PM)
After market: 7.67 0 (0%)7.67
-0.07 (-0.9%)
Company Profile
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Company Info
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139
P: 16175863100
CEO: Adrian Gottschalk
Employees: 116
Website: https://foghorntx.com/
FHTX News
10 days ago - Foghorn Therapeutics, Inc.Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors10 days ago - Foghorn Therapeutics, Inc.Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsPrimary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1...
11 days ago - Flagship PioneeringFlagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and...
17 days ago - Invaio SciencesInvaio Sciences Appoints André Andonian as Chairman of the Board of Directors/PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the...
17 days ago - Flagship PioneeringA*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore/PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, and Flagship Pioneering, the bioplatform...
19 days ago - Foghorn Therapeutics, Inc.Foghorn Therapeutics to Participate in the BMO Oncology SummitFHTX Twits
Here you can normally see the latest stock twits on FHTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
